Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

Zhao, Wei; Chen, Weixin; Li, Juan; Chen, Meng; Qin, Li; Lv, Min; Zhou, Shihao; Bai, Shuang; Wang, Yali; Zhang, Lichi; Zhang, Peng; Wang, Jian; Zheng, Qun; Wu, Jiang

doi:10.1128/mbio.00181-22

Cited by 22 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only in the first case did the antibodies increase, which would indicate that in only the participants who had new contact with the antigen or in only those in that group was the infection successful. This could be due to the low neutralizing capacity of the antibodies generated thus far in the participants without COVID-19 prior to infection (62.4%) compared to that in those with hybrid immunity (94.5%) as reported by Zhao et al ( 42 ). However, in this study, it was not possible to confirm that the number of infections was lower in a specific group.…”

Section: Discussionmentioning

confidence: 85%

Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population

et al. 2023

View full text Add to dashboard Cite

Since the start of the vaccination programs against COVID-19 in 2020, it was evident that due to global shortages, the demand for the dose required in Mexico could only be covered by acquiring different vaccines. Therefore, determining the effectiveness of these and the longevity of acquired immunity is extremely important in a scenario where SARS-CoV-2 circulation becomes endemic and booster doses are required periodically.

show abstract

Section: Discussionmentioning

confidence: 85%

Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Zhao et al. ( 18 ) and Jiang et al. ( 19 ) have studied the regulation of cytokines and lymphocytes induced by CoronaVac in a comprehensive way in their respective studies.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, Zhao et al. reported the humoral and cellular immune responses of 136 participants activated by two-dose of CoronaVac after 1, 3, 6, and 12 moths ( 18 ). Jiang et al.…”

Section: Introductionmentioning

confidence: 99%

Serum peptidome profiles immune response of COVID-19 Vaccine administration

Zhang

Li²,

Xu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings.MethodsWe performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information.ResultsSignificant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR).ConclusionsThe study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines.

show abstract

“…The initial serum antibody wanes in the absence of ongoing antigenic stimulation, but that B and T cell memory will have been primed for a speedy, protective response upon a repeat encounter. Our previous research on the functional CD4+ and CD8+ memory T cells response in participants administrated by two doses of COVID-19 inactivated vaccine suggested that the structural integrity of whole SARS-CoV-2 of inactivated vaccine might be the key to elicit antiviral CD8+ memory T-cell responses, and Th1 dominated the immune response pathway rather than the traditional Th2 [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study

Xie

Chen

et al. 2022

Vaccines

View full text Add to dashboard Cite

Amid the ongoing global COVID-19 pandemic, limited literature exists on immune persistence after primary immunization and the immunogenic features of booster vaccines administered at different time intervals. Therefore, this study aimed to determine the immune attenuation of neutralizing antibodies against the SARS-CoV-2 wild-type strain, and Delta and Omicron variants 12 months after the primary administration of the COVID-19 inactivated vaccine and evaluate the immune response after a booster administration at different time intervals. A total of 514 individuals were followed up after primary immunization and were vaccinated with a booster. Neutralizing antibodies against the wild-type strain and Delta and Omicron variant spike proteins were measured using pseudovirus neutralization assays. The geometric mean titers (GMTs) after the primary and booster immunizations were 12.09 and 61.48 for the wild-type strain, 11.67 and 40.33 for the Delta variant, and 8.51 and 29.31 for the Omicron variant, respectively. The GMTs against the wild-type strain declined gradually during the 12 months after the primary immunization, and were lower against the two variants. After implementing a booster immunization with a 6 month interval, the GMTs against the wild-type strain were higher than those obtained beyond the 7 month interval; however, the GMTs against the two variants were not statistically different across 3–12 month intervals. Overall, SARS-CoV-2 variants showed remarkable declines in immune persistence, especially against the Omicron variant. The booster administration interval could be shortened to 3 months in endemic areas of the Omicron variant, whereas an appropriate prolonging of the booster administration interval did not affect the booster immunization effect.

show abstract

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

Cited by 22 publications

References 39 publications

Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population

Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population

Serum peptidome profiles immune response of COVID-19 Vaccine administration

Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study

Contact Info

Product

Resources

About